Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes

The benefits of AID appear to be substantial for a broad spectrum of insulin-treated patients with type 2 diabetes, including those already receiving contemporary and guideline-directed therapy, such as a GLP-1 RA medication. These additive benefits of AID in GLP-1 RA users included significant reductions in HbA1c levels with simultaneous reduction in insulin use, along with no statistical increase in weight despite very significant improvements in glycemic control.

Authors

Institutions

Publication Details

Journal
Diabetes Care
Published
2025-11-20
DOI
https://doi.org/10.2337/dc25-1753
Citations
2
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
2.59
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes

A. C. B. Dean, Megan Tribout, Tess Heyerman, Heather Hunter et al.
2 citations
Diabetes Care
Diabetes Treatment and Management
2.59
article

Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes

A. C. B. Dean, Megan Tribout, Tess Heyerman, Heather Hunter, Carol J. Levy, Thomas Blevins, In‐Kyoung Lee, KIRSTIN N. WHITE, Heather Lapier, Vanessa Oduah, Deborah Branigan, Susan A. Brown, Hung V. Le, Michael Phan, Sherryl Payra, Rahaf Sultan, Philip Raskin, Cornelia Dalton-Bakes, David R. Liljenquist, Heidi Strayer, Georgia M. Davis, Jnh Vanderheide, Tram Meeks, Morgan Fuller, Ahmad Haidar, Quiana Howard, Joshua W. Smith, Omolade Oladejo, Matthew O. Howard, Agnieszka M. Lesniak, Betül Hatipoğlu, Robert Janicek, Mary C. Oliveri, Ryan Luker, Louise Vancer, Tamara Spaic, Vanessa Tardio, Dan Raghinaru, Valerie Wolf, Grenye O’Malley, Justin Rogers, Brittany Dennis, Paula Layton, Astrid Atakov-Castillo, Dori Khakpour, Donna Desjardins, Kylie Phillips, Kara DiFrancesco, Lauren Kanapka, Natalie J. Bellini, Jerry Tribout, Samina Afreen, Melanie Mellenthin, Camilla Levister, Denise Alabi, Adelaida Morales, Devin Steenkamp, Shafaq Rizvi, Jorge Jo Kamimoto, Valerie Espinosa, Frances E. Broyles, Teresa H Mitchell, Yogish C. Kudva, Emma Emory, Howard Wolpert, Jelena Kravarusic, Francisco J. Pasquel, Jane Bulger, Jesica Baran, Adrienne Terry, Davida Kruger, David T. Ahn, Grazia Aleppo, Jordan E. Pinsker, Farbod Zahedi Tajrishi, Adam Moore, W. Norman Scott, Stanley L. Marks, Alex Wheatcroft, Michael A. Tsoukas, Luis G. Arroyo, Samsam C. Penn, Amy J. Peleckis, Elias K. Spanakis, Ruth S. Weinstock, KAREN CARMELO, Emily Ellis, Roy W. Beck, Michael Roehrhoff Rickels, Andrew Ahmann, Selassie Ogyaadu, Graham John Kemp, Selina Liu, Patali Mandava, Suzan Bzdick, Chad Fields, Elizabeth Brouillard, Jasmeen Dhillon, Viola Holmes, John W. Lum, Rosanna Holod, Melissa Pasqua, Lakshmi G. Singh, Brittany Caswell, Mario Becerra, Caleb Schmid, Sheri Stone, Laura Kollar, Nicole Piquette, Corinne Aia, Ravid Sasson-Katchalski, Kathleen Estrada, Xenia Averkiou, Natalie Corker, Shereen Mukhashen, Baomei Shao, Ravinder Jeet Kaur, Jonathan Williams, Keta Pandit, Ana Stewart, Daine Livingood, Denisa Tamarez, Evelyn Fronczyk, Sabeena Usman, Claudia Lewis, Rochelle Christensen, Lisa Hendricks, Craig Kollman, Patricia Bourne, Jennifer Perez, J. Kimberly Jones, Marsha Driscoll, Kasey Coyne, Carlos Murphy, Beth Morrell, Shaziah Hassan, L.F. Jordan, Tiffany Campos, Asya Sullivan, Timothy E. Graham, Irl B. Hirsch, Stefanie Herrmann, James Malone, Deanna Gabrielson, Luis Casaubon, Aslihan Ipek, Corey Kurek, Sylvia Curtis, Raymond M. Costello, Lynn Agostini, Jade Churchill, Charles Spanbauer, David Fulkerson, Patrisia Litvicov, Sydney Swinton, Babette Hairston, Trang DoNguyen, Erica Denallo, Gabriela Cardenas-Villamil, Kevin Mercado, Stephanie Rezac, Kathleen Comen, Brian Tessman, Clemente Reyes-Rodriguez, Courtney Assir, Elyse Toole
article en
2 citations

Abstract

The benefits of AID appear to be substantial for a broad spectrum of insulin-treated patients with type 2 diabetes, including those already receiving contemporary and guideline-directed therapy, such as a GLP-1 RA medication. These additive benefits of AID in GLP-1 RA users included significant reductions in HbA1c levels with simultaneous reduction in insulin use, along with no statistical increase in weight despite very significant improvements in glycemic control.

Diabetes CareVol. 48(12)
Oregon Health & Science University (US), Southwestern Medical Center (US), Tandem Diabetes Care (United States) (US), Diabetes Care Center (US), Diabetes & Endocrine Associates (US), Diabetes & Endocrinology Specialists (US), Jaeb Center for Health Research (US), McGill University (CA), University of Virginia (US), The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 8%
Diabetes Treatment and Management
2.59
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.